semaglutide molecule Diabetes Drug Molecule, Incretin Agonist. Skeletal Formula Stock Vector Starting structure of semaglutide used

Clinical trials demonstrate unprecedented weight loss of up to 22.5% of body weight over 72 weeks , rivaling the outcomes of bariatric surgery, alongside a 2.02.4% reduction in HbA1c , achieving glycemic control unparalleled in current diabetes treatments ( 1, 2, 3 )

Nothing less

A key benefit of medically supervised weight loss is the focus on longterm maintenance

Initially developed to manage type 2 diabetes, Semaglutide has garnered attention for its potential use in weight management, even among individuals who do not have diabetes

Some people experiment with nootropics to manage attention-deficit/hyperactivity disorder, hoping to avoid stimulant medications